Revvity (NYSE:RVTY – Get Free Report) and iSpecimen (NASDAQ:ISPC – Get Free Report) are both healthcare companies, but which is the superior stock? We will compare the two businesses based on the strength of their profitability, institutional ownership, risk, valuation, analyst recommendations, dividends and earnings.
Analyst Recommendations
This is a breakdown of recent recommendations for Revvity and iSpecimen, as reported by MarketBeat.
| Sell Ratings | Hold Ratings | Buy Ratings | Strong Buy Ratings | Rating Score | |
| Revvity | 0 | 14 | 4 | 0 | 2.22 |
| iSpecimen | 1 | 0 | 0 | 0 | 1.00 |
Revvity currently has a consensus price target of $116.57, suggesting a potential downside of 18.82%. Given Revvity’s stronger consensus rating and higher possible upside, equities research analysts clearly believe Revvity is more favorable than iSpecimen.
Valuation & Earnings
| Gross Revenue | Price/Sales Ratio | Net Income | Earnings Per Share | Price/Earnings Ratio | |
| Revvity | $2.86 billion | 5.61 | $241.20 million | $2.10 | 68.38 |
| iSpecimen | $1.93 million | 1.74 | -$10.49 million | ($56.44) | -0.02 |
Revvity has higher revenue and earnings than iSpecimen. iSpecimen is trading at a lower price-to-earnings ratio than Revvity, indicating that it is currently the more affordable of the two stocks.
Volatility and Risk
Revvity has a beta of 1.09, indicating that its share price is 9% more volatile than the S&P 500. Comparatively, iSpecimen has a beta of 1.62, indicating that its share price is 62% more volatile than the S&P 500.
Institutional & Insider Ownership
86.7% of Revvity shares are owned by institutional investors. Comparatively, 13.6% of iSpecimen shares are owned by institutional investors. 0.9% of Revvity shares are owned by insiders. Comparatively, 12.2% of iSpecimen shares are owned by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock is poised for long-term growth.
Profitability
This table compares Revvity and iSpecimen’s net margins, return on equity and return on assets.
| Net Margins | Return on Equity | Return on Assets | |
| Revvity | 8.16% | 8.34% | 5.01% |
| iSpecimen | -2,445.40% | -524.39% | -140.42% |
Summary
Revvity beats iSpecimen on 12 of the 14 factors compared between the two stocks.
About Revvity
Revvity, Inc. provides health sciences solutions, technologies, and services in the Americas, Europe, and Asia, and internationally. The Life Sciences segment provides instruments, reagents, informatics, software, subscriptions, detection, imaging technologies, warranties, training, and services. Its Diagnostics segment provides instruments, reagents, assay platforms, and software products for the early detection of genetic disorders, such as pregnancy and early childhood, as well as infectious disease testing in the diagnostics market. Its products are used for testing and screening genetic abnormalities, disorders, and diseases, including down syndrome, hypothyroidism, muscular dystrophy, infertility, and various metabolic conditions. This segment also develops technologies that enable and support genomic workflows using protein coupled receptor and next-generation DNA sequencing for applications in oncology, immunodiagnostics, and drug discovery. It serves pharmaceutical and biotechnology companies, laboratories, academic and research institutions, public health authorities, private healthcare organizations, doctors, and government agencies under the AutoDELFIA, BACS-on-Beads, BIOCHIPs, Bioo Scientific,BoBs , chemagic, Chitas, DELFIA, DELFIA Xpress, DOPlify, EONIS, EUROArray, EUROIMMUN, EUROLabWorkstation, EUROLINE, EUROPattern, Evolution Evoya, explorer, Fontus, Genoglyphix, GSP, Haoyuan, IDS, IDS-i10 IDS-i10T, IDS-iSYS, iLab, iQ, JANUS, LabChip, LifeCycle, LimsLink, Migele, MultiPROBE, NEXTFLEX, NextPrep, Pannoramic, Panthera Puncher, PG-Seq, PGFind PKamp, PreNAT II, Prime, Protein Clear, ProteinEXact, QSigh, QuantiVac, RONIA, Sciclone, SimplicityChrom, Specimen Gate,Superflex, Symbio, T-SPOT, Touch, Twister, Vanadis, VariSpec, ViaCord VICTOR 2D, and Zephyr brand name. The company was formerly known as PerkinElmer, Inc. and changed its name to Revvity, Inc. in April 2023. Revvity, Inc. was founded in 1937 and is headquartered in Waltham, Massachusetts.
About iSpecimen
iSpecimen Inc. provides technology that connects life science researchers who need human biofluids, tissues, and living cells for their research with biospecimens available in healthcare provider organizations worldwide. Its cloud-based technology enables scientists to search for specimens and patients across a network of hospitals, clinics, private practice groups, laboratories, blood centers, biobanks, clinical research sites, and cadaveric donation centers. The company develops and operates iSpecimen Marketplace, a proprietary online marketplace platform that connects medical researchers who need access to subjects, samples, and data with hospitals, laboratories, and other organizations who have access to them. It serves biopharmaceutical companies, in vitro diagnostic companies, and government/academic institutions. iSpecimen Inc. was incorporated in 2009 and is headquartered in Lexington, Massachusetts.
Receive News & Ratings for Revvity Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Revvity and related companies with MarketBeat.com's FREE daily email newsletter.
